Results 31 to 40 of about 82,921 (179)

Is native E coli- or Peg-ASP more thrombogenic in adult ALL? A systematic review and meta-analysis

Thrombosis Update, 2023
Summary/background: Native Ecoli-Asparaginase (NEA)-containing regimens is an integral part of the ALL-treatment protocol for pediatric and young adults.
Jack T. Seki, Reem Alsibai, Eshetu G. Atenafu, Ruiqi Chen, Hassan Sibai   +4 more
doaj   +1 more source

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

ESMO Open, 2020
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less ...
Kjeld Schmiegelow, Patrick W Burke, Dieter Hoelzer, Jae H Park, Dan Douer   +4 more
doaj   +1 more source

RELATO DE CASO: TROMBOSE POR PEG-ASPARAGINASE EM PACIENTE COM LINFOMA LINFOBLÁSTICO DE CÉLULAS T

Hematology, Transfusion and Cell Therapy, 2023
Introdução: A PEG-Asparaginase (PEG-A) está presente em protocolos quimioterápicos de diversas doenças linfoproliferativas, sendo considerado um tratamento agressivo e com múltiplos efeitos colaterais, inclusive a trombose. Objetivo: Relatar caso clínico
BK Losch, FK Tornquist, EW Silva, TS Hahn, AH Schuck, MFL Pezzi, LV Calderan, LM Lorenzini, ACF Segatto   +8 more
doaj   +1 more source

Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study [PDF]

, 2019
PURPOSE Asparaginase is an essential drug in childhood acute lymphoblastic leukemia (ALL) therapy and is frequently given for months to obtain continuous asparagine depletion.
Lund, B., Albertsen, B. K., Schmiegelow, K., Jonsson, O. G., Wolthers, B. O., Heyman, M, Grell, K, Abrahamsson, J, Albertsen, BK, Jonsson, OG, Lund, B, Grell, K., Heyman, M., Frandsen, T. L., Vettenranta, K., Vettenranta, K, Wolthers, BO, Frandsen, TL, Schmiegelow, K, Abrahamsson, Jonas,   +19 more
core   +5 more sources

A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase [PDF]

, 2009
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism.
Vaskar Saha, Krishnan, S., Holland, Mark, Colin Watts, Mark Holland, Holland, M., Liu, JiZhong, Ariffin, Hany, Bates, P.A., Marcin Krol, Paul A. Bates, Moss, Catherine X., Patel, N., Essink, M., Patel, Naina, Clare Dempsey, Krishnan, Shekhar, van Delft, Frederik W., Watts, Colin, Carly Leighton, Leighton, Carly, Eden, T.O.B., Moss, C.X., Offman, Marc N., JiZhong Liu, Dempsey, Clare, Seema Alexander, Hany Ariffin, Bates, Paul A., Dempsey, C., Eden, Tim O B, Alexander, S., van Delft, F.W., Frederik W. van Delft, Watts, C., Offman, M.N., Saha, V., Leighton, C., Eden, Tim O.B., Saha, Vaskar; id_orcid, Shekhar Krishnan, Monika Essink, Saha, Vaskar, Krol, Marcin, Ariffin, H., Tim O.B. Eden, Naina Patel, Alexander, Seema, Catherine X. Moss, Krol, M., Marc N. Offman, Liu, J.Z., Essink, Monika   +52 more
core   +1 more source

IgG Antibodies Cannot Explain Silent Inactivation in PEG-Asparaginase Treatment [PDF]

, 2018
Background/Objectives: PEG-asparaginase represents a key element in the treatment of acute lymphoblastic leukemia (ALL), however allergic reactions and lack of asparaginase enzyme activity shortly after administration (silent inactivation) constitutes a ...
Lähtenmäki, P, Heyman, Mats, Harila-Saari, A, Jonsson, OG, Albertsen, BK, Pruunsild, K, Lund, B, Henriksen, LT, Nersting, J, Vaitkeviciene, G, Schmiegelow, K, Gottschalk Højfeldt, S, Abrahamsson, Jonas,   +12 more
core   +1 more source

Reusability of the 1kDa-PEG-conjugate. [PDF]

, 2018
Relative catalytic activity at temperatures ranging from 20°C to 80°C. The 1kDa-PEG-conjugate (in green), native L-asparaginase (in blue), and a commercial randomly-PEGylated L-asparaginase formulation (Millipore Sigma, USA) (in black).
Josell Ramirez-Paz (3852553), Virginia A. Rojas-Nieves (5565800), Zhongfang Chen (1288152), Kai Griebenow (23303), Manoj Saxena (2624236), Louis J. Delinois (5565791), Shiru Lin (5565797), Freisa M. Joaquín-Ovalle (5565794)   +7 more
core   +1 more source

Preliminary Report on Protein Preparations Exhibiting Both Asparaginase and Glutaminase Activity Purified from Rhodococcus Rhodochrous DAP 96253 [PDF]

, 2022
Bacterial L-Asparaginase has been utilized along with chemotherapy in the treatment of acute lymphoblastic leukemia. Current forms of treatment are fraught with undesirable outcomes in a significant number of cases.
Amadasun, Nosazena
core   +2 more sources

RELATO DE CASO: PANCREATITE AGUDA RECIDIVANTE SECUNDÁRIA À PEG-ASPARAGINASE

Hematology, Transfusion and Cell Therapy, 2023
Introdução: A pancreatite medicamentosa é uma condição rara, sendo uma manifestação frequente relacionada aos quimioterápicos, entre eles, a PEG-asparaginase (PEG-ASP) é uma das principais drogas associadas, tanto na população pediátrica quanto adulta ...
TS Hahn, GCL Bellini, JF Knaach, EW Silva, MFL Pezzi, AH Schuck, LV Calderan, BK Losch, LM Lorenzini, ACF Segatto, A Kittel, KCN Corbellini   +11 more
doaj   +1 more source

Possible mechanism of metabolic and drug resistance with L-asparaginase therapy in childhood leukaemia

Frontiers in Oncology, 2023
L-asparaginase, which hydrolyzes asparagine into aspartic acid and ammonia, is frequently used to treat acute lymphoblastic leukaemia in children. When combined with other chemotherapy drugs, the event-free survival rate is 90%. Due to immunogenicity and
Ruizhi Zhou, Tianqi Liang, Tianwen Li, Junbin Huang, Chun Chen   +4 more
doaj   +1 more source